JCR Pharmaceuticals' forecast for ordinary profit for the fiscal year ending March 2027 fell 21% week on week to ¥513 million. The forecast decline from the previous year's results has widened, and views that it is slightly bullish versus the company forecast of ¥500 million are becoming more widespread.
The consensus forecast for ordinary profit fell 21% from ¥650 million the previous week to ¥513 million. The decline from the previous year's results has widened, and the forecast has been revised down to a 55.9% decline.
The company forecast is ¥500 million, while the current consensus is slightly bullish.
The rating consensus rose from 3.2 to 3.5.